Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

作者：Moreau Philippe; Attal Michel; Pegourie Brigitte; Planche Lucie; Hulin Cyrille; Facon Thierry; Stoppa Anne Marie; Fuzibet Jean Gabriel; Gro**ois Bernard; Doyen Chantal; Ketterer Nicolas; Sebban Catherine; Kolb Brigitte; Chaleteix Carine; Dib Mamoun; Voillat Laurent; Fontan Jean; Garderet Laurent; Jaubert Jerome; Mathiot Claire; Esseltine Dixie; Avet Loiseau Herve; Harousseau Jean Luc^*

来源：Blood, 2011, 117(11): 3041-3044.

DOI：10.1182/blood-2010-08-300863

In the 2005-01 trial, we have demonstrated that bortezomib-dexamethasone as induction therapy before autologous stem cell transplantation was superior to vincristine-adriamycin-dexamethasone. We conducted a post-hoc analysis to assess the prognostic impact of initial characteristics as well as response to therapy in patients enrolled in this study. Multivariate analysis showed that ISS stages 2 and 3 and achievement of response less than very good partial response (VGPR) both after induction therapy and after autologous stem cell transplantation were adverse prognostic factors for progression-free survival, the most important one being achievement of response less than VGPR after induction. Progression-free survival was significantly improved with bortezomib-dexamethasone induction therapy in patients with poor-risk cytogenetics and ISS stages 2 and 3 compared with vincristine-adriamycin-dexamethasone. In these 2 groups of patients, achievement of at least VGPR after induction was of major importance. This study is registered with EudraCT (https://eudract.ema.europa.eu; EUDRACT2005-000537-38) and http://clinicaltrials.gov (NCT00200681). (Blood. 2011; 117(11):3041-3044)

• 出版日期2011-3-17